US Pharma MarketingFDA delays Leqembi decision; Artiva raises $300M on RA data; Pharvaris prices offering
FDA delays subcutaneous Leqembi decision; Artiva touts rheumatoid arthritis data, prices $300M raise; Pharvaris also priced a $115 million offering on Friday. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…
🗓️ FDA delays subcutaneous Leqembi decision: Originally slated for later this month, the decision date now falls on August 24, Biogen and Eisai said. The agency asked for more information from ...
Source: Endpoints News